144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

• Post author:andrewkaretas
• Post published:March 14, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

• Post author:andrewkaretas
• Post published:March 14, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

S-8: Securities offered to employees pursuant to employee benefit plans

• Post author:andrewkaretas
• Post published:March 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingS-8: Securities offered to employees pursuant to employee benefit plans

10-K: Annual report which provides a comprehensive overview of the company for the past year

• Post author:andrewkaretas
• Post published:March 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading10-K: Annual report which provides a comprehensive overview of the company for the past year

8-K: Report of unscheduled material events or corporate event

• Post author:andrewkaretas
• Post published:March 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

• Post author:andrewkaretas
• Post published:March 13, 2025
• Post category:Latest News

Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with…

Continue ReadingAllogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

March 13, 2025 5:00 PM EDT : The Allogene Therapeutics Fourth Quarter 2024 Conference Call

• Post author:andrewkaretas
• Post published:March 11, 2025
• Post category:Events

Continue ReadingMarch 13, 2025 5:00 PM EDT : The Allogene Therapeutics Fourth Quarter 2024 Conference Call

SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:March 7, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A – Description

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:March 5, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

3: Initial filing by director officer or owner of more than ten percent

• Post author:andrewkaretas
• Post published:March 4, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading3: Initial filing by director officer or owner of more than ten percent